Porous tantalum acetabular cups for reconstructions after peri-acetabular resections of primary bone tumours

2021 ◽  
pp. 112070002110015
Author(s):  
Riccardo Zucchini ◽  
Andrea Sambri ◽  
Claudio Giannini ◽  
Michele Fiore ◽  
Carlotta Calamelli ◽  
...  

Introduction: Periacetabular reconstruction after resection of primary bone tumour is a very demanding procedure. They are frequently associated with scarce functional results and a high rate of complications. We report a series of patients with periacetabular resections for primary bone tumours and reconstruction with a porous tantalum (PT) acetabular cup (AC). Materials and methods: 27 patients (median age 30 years) were included, being affected by primary bone tumours of the pelvis and treated with peri-acetabular resection and reconstruction with a PT AC. The diagnoses were 13 osteosarcomas, 7 chondrosarcomas and 7 Ewing sarcomas. Function was assessed with the Harris Hip Score and complications were classified according to Zeifang. Results: The median follow-up was 70 months. 1 patient required removal of the PT AC because of implant associated infection 55 months after surgery. There was 1 hip dislocation and no case of aseptic loosening. At final follow-up, the median HHS was 81 points (range 48–92). Conclusions: The used PT AC had good medium-term survival rates and good functional results. This technique is a viable reconstructive option after resections of periacetabular primary bone sarcomas.

1995 ◽  
Vol 20 (1) ◽  
pp. 5-7 ◽  
Author(s):  
D. A. CAMPBELL ◽  
P. A. MILLNER ◽  
C. R. DREGHORN

Primary bone tumours are rare in the hand and wrist. This 34-year survey of the Leeds Regional Bone Tumour Registry reveals 80 such tumours, representing 3.9% of the total number of bone turnouts in the registry. The large majority of these tumours were benign (86%), and were found predominantly in younger patients. Malignant lesions were found more frequently in older patients. 61% of tumours were found in the metacarpals and proximal phalanges. Two-thirds of patients (67.5%) presented with features of swelling, either with or without pain. We conclude that the information gathered from Bone Tumour Registries is of value in describing tumour characteristics, where such information could not be gathered by personal experience alone.


The Foot ◽  
1991 ◽  
Vol 1 (3) ◽  
pp. 135-138 ◽  
Author(s):  
Roger H. Helm ◽  
Raymond J. Newman

2006 ◽  
Vol 16 (3) ◽  
pp. 405-409 ◽  
Author(s):  
Simon P. Kelley ◽  
Robert U. Ashford ◽  
Abhay S. Rao ◽  
Robert A. Dickson

2012 ◽  
Vol 18 (4) ◽  
pp. 277-282 ◽  
Author(s):  
S.W. Bell ◽  
P.S. Young ◽  
A. Mahendra

Author(s):  
Philip O. Akpa ◽  
Barka V. Kwaghe ◽  
Christiana Nwanneka Ibeanu ◽  
Pricilla Ometere Onota

Aims: This study aims to document the age, sex and site distribution of fibrous dysplasia in our tertiary health care facility in order to compare our findings with published literature. Study Design: This is a hospital-based retrospective and descriptive study extending from 1st January 2005 to 31st December 2019. Place and Duration of Study: Department of Histopathology, Jos University Teaching Hospital, Jos, Plateau State in North-Central Nigeria between 1st January 2005 to 31st December 2019. Materials and Methods: Materials consisted of Archival slides, paraffin wax tissue blocks, surgical pathology register and case files of all cases of fibrous dysplasia diagnosed histologically during the period of review. The age, sex and site affected by the tumour were documented for each case using both electronic and hard copy records. The histology slides were examined to confirm the diagnosis. A total of 165 primary bone tumours (103 benign and 63 malignant) were recorded during the period of review, of which 28 were fibrous dysplasia. Results: There were 28 cases of fibrous dysplasia which represented 17% of the primary bone tumours and 27% of the benign bone tumours. A half (50%) of the cases occurred in the second decade and 82.1% of cases were diagnosed in craniofacial bones. There was no sex bias in diagnosis. Conclusion: Fibrous dysplasia is a relatively common bone tumour in our environment. The sex distribution, age at diagnosis, and bones affected is in keeping with findings by authors from other parts of the world.


2019 ◽  
Vol 101-B (5) ◽  
pp. 502-511 ◽  
Author(s):  
S. Lidder ◽  
D. J. Epstein ◽  
G. Scott

Aims Short-stemmed femoral implants have been used for total hip arthroplasty (THA) in young and active patients to conserve bone, provide physiological loading, and reduce the incidence of thigh pain. Only short- to mid-term results have been presented and there have been concerns regarding component malalignment, incorrect sizing, and subsidence. This systematic review reports clinical and radiological outcomes, complications, revision rates, and implant survival in THA using short-stemmed femoral components. Materials and Methods A literature review was performed using the EMBASE, Medline, and Cochrane databases. Strict inclusion and exclusion criteria were used to identify studies reporting clinical and radiological follow-up for short-stemmed hip arthroplasties. Results A total of 28 studies were eligible for inclusion. This included 5322 hips in 4657 patients with a mean age of 59 years (13 to 94). The mean follow-up was 6.1 years (0.5 to 20). The mean Harris Hip Score improved from 46 (0 to 100) to 92 (39 to 100). The mean Oxford Hip Score improved from 25 (2 to 42.5) to 35 (12.4 to 48). The mean Western Ontario & McMaster Universities Osteoarthritis Index improved from 54 (2 to 95) to 22 (0 to 98). Components were aligned in a neutral coronal alignment in up to 90.9% of cases. A total of 15 studies reported component survivorship, which was 98.6% (92% to 100%) at a mean follow-up of 12.1 years. Conclusion Short-stemmed femoral implants show similar improvement in clinical and radiological outcomes compared with conventional length implants. Only mid-term survivorship, however, is known. An abundance of short components have been developed and used commercially without staged clinical trials. Long-term survival is still unknown for many of these components. There remains tension between innovation and the moral duty to ensure that the introduction of new implants is controlled until safety and patient benefit are demonstrated. Implant innovation and subsequent use should be driven by proven clinical outcomes, rather than market and financial forces, and ethical practice must be ensured. Cite this article: Bone Joint J 2019;101-B:502–511.


Sign in / Sign up

Export Citation Format

Share Document